RX BioSyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About BioSyent (CVE: RX)
›
BioSyent (CVE: RX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 17.49 CAD on 19 November 2026, up 63.2% over 52 weeks. Its 52-week range is 10.65 CAD to 18.40 CAD: the price is 4.9% below the high and 64.2% above the low.
At a market capitalisation of 196.45M CAD, it trades at 20.6 times trailing earnings and 31.2 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 17% for RX. It pays a dividend yielding 1.24% (it pays out 25% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
BioSyent reports return on equity of 21.7%, an operating margin of 21.5% and revenue up 64.3% year over year.
It holds more cash than debt, a net cash position of 12.98M CAD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. One analyst covers the stock; their mean price target of 18.00 CAD is 2.9% above the current price.